SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about company updates

30 Jan 2020 Evaluate

Further to intimations dated 7th & 11th October, 2019 with regard to the USFDA inspection of Unit VII, an oral solids formulation manufacturing facility of the Company, Aurobindo Pharma has informed that the Company has received a letter from the USFDA classifying the inspection conducted at the aforesaid facility as Official Action Indicated (OAI). This OAI classification will not have any material impact on the existing revenues or the supplies to its US business at this juncture. The Company will work closely with the regulator to comprehensively address the issues. 

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1440.30 4.40 (0.31%)
24-Apr-2026 09:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1648.15
Dr. Reddys Lab 1304.40
Cipla 1267.50
Zydus Lifesciences 942.25
Lupin 2335.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×